While there is data to suggest that some HSP90 client protein interactions occur without HSP70 involvement, we hypothesized that disrupting the HSP70/90 cycle in MIBC may be a more effective anti-cancer treatment than HSP90 inhibition alone [35]. The gene discussed is HSP90AA1; the disease is cancer.